RT Journal Article
SR Electronic
A1 Rizzo, Tony
T1 Two Years versus One Year of Trastuzumab in Patients with Early Breast Cancer
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 15
SP 11
OP 12
DO 10.1177/155989771215007
UL http://mdc.sagepub.com/content/12/15/11.abstract
AB The 2005 results of large randomized trials, including the Trastuzumab in Treating Women with Primary Breast Cancer [HERA; NCT00045032] trial, demonstrated statistically significant disease-free survival benefit for 1 year of treatment with trastuzumab compared with observation in patients with human epidermal growth factor receptor 2-positive early breast cancer. After 2005, the HERA trial focused on the secondary objective of comparing 2 years of trastuzumab treatment with 1 year of treatment, and this article discusses the results of this analysis.